Fig. 2.

Nusinersen levels in the CSF in DEVOTE Part A are greater than those with the 12-mg dose, as predicted by the population PK model. Individual level DEVOTE Part A data of nusinersen concentrations in the CSF (C_trough) show steady increase through the loading dose period and reaching median concentration of 8.7 ng/mL on Day 29. On Day 269, the last measurement in Part A, the observed median pre-dose CSF C_trough was 10.2 ng/mL. The predicted CSF C_trough for the 12-mg dose regimen are 6.1 ng/mL on Day 29 and 5.6 ng/mL on Day 269. CSF levels of nusinersen increased during loading. CSF, cerebrospinal fluid.